NCT05411081 2026-03-19
Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
29 trialsNCT05773274 2026-03-19
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT02243605 2026-03-18
Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03866382 2026-03-18
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04071223 2026-03-18
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04079712 2026-03-18
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06900595 2026-03-18
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05136196 2026-03-17
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT03945773 2026-03-13
CaboPoint
Ipsen
Phase 2 Completed
NCT05019703 2026-03-11
Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05012371 2026-03-05
Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05425004 2026-03-05
Cabozantinib for Patients With Recurrent or Progressive Meningioma
Baptist Health South Florida
Phase 2 Recruiting
NCT04091750 2026-03-03
Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma
Georgetown University
Phase 2 Active not recruiting
NCT05048212 2026-03-02
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT01068782 2026-02-25
Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse
Exelixis
Phase 2 Terminated
NCT06006013 2026-02-18
Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer
Emory University
Phase 2 Recruiting
NCT04963283 2026-02-10
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
University of Colorado, Denver
Phase 2 Active not recruiting
NCT07077161 2026-01-28
SKIPPY 2
Leiden University Medical Center
Phase 2 Recruiting
NCT03468218 2026-01-23
Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer
Emory University
Phase 2 Active not recruiting
NCT05502315 2026-01-23
CANOPY
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT04413123 2026-01-21
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04876456 2026-01-15
A Phase II Trial of Cabozantinib With Patients With Refractory GCTs
Indiana University
Phase 2 Active not recruiting
NCT05327686 2026-01-14
SAMURAI
NRG Oncology
Phase 2 Recruiting
NCT03541902 2026-01-09
Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01995058 2026-01-08
Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC
Exelixis
Phase 2 Terminated
NCT05613413 2026-01-08
LUNG-IST-127
University of Illinois at Chicago
Phase 2 Recruiting
NCT04820179 2026-01-07
Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer
University of Arizona
Phase 2 Active not recruiting
NCT04022343 2026-01-05
Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer
Emory University
Phase 2 Active not recruiting
NCT04200443 2026-01-05
Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma
City of Hope Medical Center
Phase 2 Active not recruiting